If item 8.5 is less than 2 quarters, please provide answers to...

If item 8.5 is less than 2 quarters, please provide answers to the following questions:8.6.1 Does the entity expect that it will continue to have the current level of net operatingcash flows for the time being and, if not, why not?

Answer: Whilst a net cash outflow is reported for the June Quarter and operatingexpenditure is expected to remain at a comparable level for future quarters, Acruxexpects to receive the Research and Development Tax Incentive for FY23 from theAustralian Federal Government before the end of 2024 and the first material profitshare income for Prilocaine 2.5% and Lidocaine 2.5% cream is due to be receivedin the September quarter.

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise furthercash to fund its operations and, if so, what are those steps and how likely does itbelieve that they will be successful?
Answer: No
8.6.3 Does the entity expect to be able to continue its operations and to meet its businessobjectives and, if so, on what basis?
Answer: Yes


Also, from the approval release
Annual market sales for prilocaine 2.5% and lidocaine 2.5% cream products for the 12 months ending October 2022 were approximately $39 million as measured by IQVIA.

And from this one

Following departure of the market leader for Prilocaine 2.5% and Lidocaine 2.5% Cream which was announced in February 2023 IQVIA market data shows that our commercial licensee for the product is achieving a strong market position.


The company's putting a lot of stock in this analgesic's ability to turn things around and stem the bleeding in the short term. Hope they're right.